These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25042271)

  • 1. Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome.
    De Palma R; James S; Jüni P; Cuisset T
    EuroIntervention; 2014 Jul; 10(3):408-10. PubMed ID: 25042271
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
    Ferreiro JL; Ueno M; Tello-Montoliu A; Tomasello SD; Seecheran N; Desai B; Rollini F; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2013 Feb; 6(2):182-4. PubMed ID: 23428011
    [No Abstract]   [Full Text] [Related]  

  • 3. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use.
    Grotti S; Bolognese L
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):121-130. PubMed ID: 31645108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
    Cayla G; Collet JP; Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
    Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
    Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
    Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
    N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 14. [The ACCOAST study].
    De Servi S; Menozzi A; De Luca L
    G Ital Cardiol (Rome); 2014 May; 15(5):276-82. PubMed ID: 25002165
    [No Abstract]   [Full Text] [Related]  

  • 15. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.
    Deharo P; Bassez C; Bonnet G; Pankert M; Quilici J; Lambert M; Verdier V; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2013 Dec; 170(2):e21-2. PubMed ID: 24231059
    [No Abstract]   [Full Text] [Related]  

  • 16. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
    Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
    Thomas MR; Storey RF
    J Cardiovasc Transl Res; 2014 Feb; 7(1):19-28. PubMed ID: 24309957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of dual antiplatelet therapy in acute coronary syndrome.
    Wilson SJ; Newby DE; Dawson D; Irving J; Berry C
    Heart; 2017 Apr; 103(8):573-580. PubMed ID: 28249994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.
    Riesmeyer JS; Salazar DE; Weerakkody GJ; Ni L; Wrishko RE; Ernest CS; Luo J; Li YG; Small DS; Rohatagi S; Macias WL
    J Clin Pharmacol; 2012 Jun; 52(6):789-97. PubMed ID: 21628601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.